RyVent (carbinoxamine maleate) NDC 15370-130

NDC codes

FDA NDC Directory

Product NDC (as listed)15370-130Labeler and product segments. Claims need a package NDC.

Product NDC at billing width15370-0130Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
15370-130-02	15370013002	2 TABLET in 1 BOTTLE, PLASTIC (15370-130-02)Marketed from Feb 17, 2017
15370-130-10	15370013010	100 TABLET in 1 BOTTLE, PLASTIC (15370-130-10)Marketed from Feb 17, 2017

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): RyVent
Generic name (nonproprietary): carbinoxamine maleate
Active ingredients: Carbinoxamine maleate — 6 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Carwin Pharmaceutical Associates, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 207484
Marketing start: Feb 17, 2017
Listing expires: Dec 31, 2026
Other FDA classes: Histamine H1 Receptor Antagonists (Mechanism)
Identifiers: Product ID 15370-130_0e84f4a5-7637-6b55-e063-6294a90a4d55SPL ID 0e84f4a5-7637-6b55-e063-6294a90a4d55SPL set ID 13ed76c7-49bd-4527-83dc-b4c7d0da9fffRxCUI 1795581, 1869883UNII 02O55696WHUPC 0315370130104
Pharmacologic class: Histamine-1 Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N415370013002 followed by a unit qualifier and the quantity

Package 15370-0130-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 9, 2024.

Indications (excerpt from the label)

INDICATIONS AND USAGE Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 207484

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 207484
Product	Strength	Form · route	Labeler	Product NDC
Carbinoxamine Maleate	Carbinoxamine maleate 6 mg/1	TabletOral	BluCrest Pharmaceuticals, LLC	73684-110